Is DiaMedica Therapeutics Inc. (DMAC) a Buy, Sell, or Hold?
NASDAQ : DMAC
DiaMedica Therapeutics Inc.
$7.13 USD
-$0.51 (-6.68%)
- Volume
- 158.62K
- Average Volume
- 199.28K
- Market Capitalization
- $384.19M
- P/E Ratio
- -10.76
- Dividend Yield
- 0.00%
- Price Target
- $8.00
- Year High
- $10.42
- Year Low
- $3.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.11
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Dietrich John Pauls |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DMAC |
| CUSIP | 25253X207 |
| CIK | 0001401040 |
| Web | https://www.diamedica.com |
| Phone | 763 612 6755 |
| Currency | USD |
| Employees | 35 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.11 |
| Quick Ratio | 9.11 |
| Cash Ratio | 0.85 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.58 |
| Price / Cash Flow | -13.24 |
| Price / Book | 8.70 |
Price Target and Rating
| Average Stock Price Forecast | $8.00 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -10.88% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.7 |
| Trailing P/E Ratio | -10.76 |
| PEG Ratio | 1.02 |
| P/E Growth | 1.02 |
| Net Income | -$32.77M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -77.09% |
| Return on Assets | -66.13% |
Financials Score
| AltmanZ Score | 35.15 |
| Piotroski Score | 2.00 |
| Working Capital | 46.62M |
| Total Assets | 53.08M |
| Ebit | -35.07M |
| Market Cap | 400.35M |
| Total Liabilities | 5.84M |
Poll Results
About DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Stock
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current ... name, DiaMedica Therapeutics Inc., in December 2016.
2026-06-23 09:00:00
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction a
2026-06-23 08:30:00
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal growth restriction (FGR). This is the first clinical evaluation of DM199 in FGR. The open-label, single-arm study is design.
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
2026-06-16 08:30:00
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia (PE). DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive toxi.
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
2026-05-27 16:30:00
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026. Jefferies Global Healthcare Conference Date: Thursday, June 4, 2026 Time: 3:45 PM ET Format: Corporate Presentation If you are interested in.
2026-05-20 08:30:00
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in patients with acute ischemic stroke (AIS) has reached 75% of the 200-patient threshold required to trigger the planned interim analysis. The Company reiterates its guida.
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-12 16:15:00
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its President and CEO, Rick Pauls, will participate in a fireside chat at the upcoming 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19th in New York City. Fireside Chat Details Date & Time: Tuesday, May 19, 2026 | 4:05-4:30.
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
2026-05-07 15:11:18
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
2026-05-06 16:30:00
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the quarter ended March 31, 2026. Management will host a conference call on Thursday, May 7, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss the Company's business update a.
Frequently Asked Questions
-
What is the current DiaMedica Therapeutics Inc. (DMAC) stock price?
-
DiaMedica Therapeutics Inc.(NASDAQ:DMAC) stock price is $7.13 in the last trading session. During the trading session, DMAC stock reached the peak price of $10.4195 while $3.65 was the lowest point it dropped to. The percentage change in DMAC stock occurred in the recent session was --6.68% while the dollar amount for the price change in DMAC stock was -$0.51.
-
DMAC's industry and sector of operation?
-
The NASDAQ listed DMAC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DMAC?
-
Dietrich John Pauls | President, Chief Executive Officer & Director
Dominic R. Cundari | Chief Commercial Officer
Ambarish Shah | Chief Technology Officer
Julie Krop | Chief Medical Officer
Scott Kellen | Chief Financial Officer & Corporate Secretary -
How many employees does DMAC have?
-
Number of DMAC employees currently stands at 35. DMAC operates from Two Carlson Parkway, Minneapolis, MN 55447, US.
-
Link for DMAC official website?
-
Official Website of DMAC is: https://www.diamedica.com
-
How do I contact DMAC?
-
DMAC could be contacted at phone #763 612 6755 and can also be accessed through its website. DMAC operates from Two Carlson Parkway, Minneapolis, MN 55447, US.
-
How many shares of DMAC are traded daily?
-
The average number of DMAC shares traded daily for last 3 months was 199.28K.
-
What is the market cap of DMAC currently?
-
The market value of DMAC currently stands at $384.19M with its latest stock price at $7.13